All In MedTech

Device Trial Radar · NCT07656818

Non-Thermal Plasma to Reduce Recurrence in Chronic Subdural Hematoma

Application of Non-Thermal Plasma in the Surgical Bed of Chronic Subdural Hematoma to Reduce the Post-Drainage Recurrence Rate: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Feb 28, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Benjamín Gonzalo Rodríguez MéndezAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centro Medico Issemym
First posted
Jun 18, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized controlled trial is to evaluate whether the adjuvant application of non-thermal plasma (NTP) during standard surgical drainage of chronic subdural hematoma (cSDH) can reduce the recurrence rate at 6 months. The main questions it aims to answer are: * Does NTP application significantly lower the radiological and clinical recurrence rate of cSDH compared to surgery alone? * Is NTP safe when applied to the subdural space and surgical wound bed? * Does NTP improve functional outcomes and time to hematoma resolution? Participants will be randomly assigned to one of two groups: * Experimental group (n = 20): Standard burr hole drainage or craniotomy plus intraoperative NTP application over the exposed dura mater, the residual membrane, soft tissue layers, and the skin incision. * Control group (n = 20): Standard surgical drainage alone (no NTP). Follow-up includes clinical assessments and computed tomography (CT) scans at 1 week, 3 months, and 6 months post-surgery. The primary outcome is recurrence (symptomatic reaccumulation requiring re-intervention or ≥50% volume increase on CT).

Conditions

  • Chronic Subdural Hematoma
  • Subdural Hematoma
  • Recurrence
  • Postoperative Complications

Interventions

  • Standard Surgery ProtocolProcedure

    Standard burr hole drainage or craniotomy for chronic subdural hematoma, including complete evacuation of the collection and placement of a subdural drain if clinically indicated. No NTP is applied.

  • Non-Thermal PlasmaDevice

    Standard surgical drainage as described above, followed by intraoperative application of non-thermal plasma (NTP) generated with helium gas (13.56 MHz RF generator, 20 Watts, flow 0.5 LPM). The plasma is applied sequentially and uniformly over: (i) the exposed dura mater and residual parietal membrane in the subdural space, (ii) the soft tissue layers during closure, and (iii) the skin incision after closure. Application time: approximately 60 seconds per 5 cm² area at a distance of 5 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Rate of Chronic Subdural HematomaTime frame: 6 months post surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Plasma Physics Laboratory, National Institute of Nuclear Research

    Ocoyoacac, State of Mexico, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.